

**Specimen Collected:** 5/6/2025 08:12 MDT**Medium Chain Acyl-CoA Dehydrogenase PCR** | **Received:** 5/6/2025 08:12 MDT **Report/Verified:** 5/7/2025 15:50 MDT

Procedure	Result	Units	Reference Interval
MCAD_PCR Specimen	Whole Blood		
MCAD A985G	<b>Homozygous *</b>		
MCAD T199C	Negative		
Medium Chain Acyl-CoA Interpretation	See Note <sup>f1 i1</sup>		

**Result Footnote**

f1: Medium Chain Acyl-CoA Interpretation

Indication for testing: Carrier screening or diagnostic testing for MCAD deficiency.

## Result

A985G: Homozygous

T199C: Negative

This sample is homozygous for the severe pathogenic variant c.985A>G in the ACADM gene; therefore, the patient is affected with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Genetic and dietary consultations are indicated. Family members should be offered targeted testing for the identified pathogenic variant. The patient's reproductive partner should be offered carrier testing for MCAD.

This result has been reviewed and approved by [REDACTED]

**Test Information**

i1: Medium Chain Acyl-CoA Interpretation

**BACKGROUND INFORMATION: Medium Chain Acyl-CoA Dehydrogenase PCR**

**CHARACTERISTICS:** Limited mitochondrial fatty acid beta-oxidation leading to hypoglycemia, lethargy, seizures, hypoketotic aciduria, vomiting, hepatomegaly, hepatic failure, encephalopathy, and sudden death. Manifestations often triggered by prolonged fasting or other metabolic stressors.

**INCIDENCE:** 1 in 15,000**INHERITANCE:** Autosomal recessive.**CAUSE:** Deleterious ACADM gene mutations.**CLINICAL SENSITIVITY:** 75 percent for MCAD deficiency.**MUTATIONS TESTED:** ACADM mutations c.985A>G (p.K329E, also known as K304E) and c.199T>C (p.Y67H, also known as Y42H).**METHODOLOGY:** Polymerase chain reaction (PCR) and fluorescence monitoring.**ANALYTICAL SENSITIVITY AND SPECIFICITY:** 99 percent.**LIMITATIONS:** Diagnostic errors can occur due to rare sequence variations. ACADM mutations other than c.985A>G and c.199T>C will not be detected.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

**Unless otherwise indicated, testing performed at:****ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 25-126-900019**Report Request ID:** 20431753**Printed:** 5/8/2025 11:16 MDT

Page 1 of 2

Patient Age/Sex: 32 years Female

---

**Test Information**

i1: Medium Chain Acyl-CoA Interpretation  
Administration. This test was performed in a CLIA certified laboratory and is  
intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms  
are available online

---

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

---

***Unless otherwise indicated, testing performed at:***

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 25-126-900019

**Report Request ID:** 20431753

**Printed:** 5/8/2025 11:16 MDT

Page 2 of 2